Membranoproliferative glomerulonephritis diagnostic study of choice

Jump to navigation Jump to search

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis diagnostic study of choice

CDC on Membranoproliferative glomerulonephritis diagnostic study of choice

Membranoproliferative glomerulonephritis diagnostic study of choice in the news

Blogs on Membranoproliferative glomerulonephritis diagnostic study of choice

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:

Overview

Diagnostic study of choice

Study of choice

  • Renal biopsy is the gold standard diagnostic test for the diagnosis of membranoproilferative glomerulonephritis[1]19908070 .
  • Light microscopy, electron dense microscopy and immunofluorescence are performed on the renal biopsy sample.
  • Other tests include
    • CBC,
    • Urine analysis
    • Renal function tests
    • Serum ANA
    • Serum complement profile
    • Antistreptolysin-O titres
    • Hepatits B and Hepatitis C
    • Blood cultures
    • Serum and urine electrophoresis[2]
  • These tests must be performed when a patient presents with anorexia, malaise, edema, secondary hypertension and oliguria.

Diagnostic results

Light microscopy
  • The findings of glomerulus with increased mesangial cellularity, increase in the mesangial matrix, and thickened peripheral capillary walls are confirmatory for the disease.
Electron microscopy
  • Immune deposits in the mesangium and subendothelial space.
Immunoflourescence
  • Presence of immunoglbulins or complement in the mesangium depending on the cause.
CBC
  • Normocytic normochromic anemia
Urine analysis
  • May show proteinuria
Renal function tests
  • Serum creatinine and BUN might be elevated
Complement profile
  • C3, C4 and CH50 levels for classic complement pathway
  • AH50 levels for alternate complement pathway
  • C3 nephritic factor levelsj[3]
Serum ANA
  • Postive serum ANA means autoimmune disease etiology
Blood culture
  • Chronic bacterial infections

Diagnostic criteria

There is no established diagnostic criteria for membranoproliferative glomerulonephritis

References

  1. Sethi S, Fervenza FC (2012). "Membranoproliferative glomerulonephritis--a new look at an old entity". N Engl J Med. 366 (12): 1119–31. doi:10.1056/NEJMra1108178. PMID 22435371.
  2. Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP; et al. (2015). "Diagnosis of monoclonal gammopathy of renal significance". Kidney Int. 87 (4): 698–711. doi:10.1038/ki.2014.408. PMID 25607108.
  3. Bourke E, Campbell WG, Piper M, Check IJ (1989). "Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma". Nephron. 52 (3): 231–7. doi:10.1159/000185648. PMID 2662048.